Effects of cardiac resynchronization therapy on insulin-like growth factor-1 in patients with advanced heart failure

Journal of Cardiovascular Medicine

Volumn 8, Issue 11, 2007, Pages 917-922

  Molon, Giulio ^a   Adamo, Edoardo ^a   De Ferrari, Gaetano M ^b   Accardi, Francesco ^c   Vecchia, Eros Dalla ^c   Sallusti, Luciano ^c   Ciaffoni, Stefano ^a   Barbieri, Enrico ^a  

^a SACRO CUORE DON CALABRIA HOSPITAL   (Italy)

^b FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^c Guidant Italia   (Italy)

Author keywords

Cardiac resynchronization therapy; CRT; Heart failure; IGF 1; Neurohormones

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; SOMATOMEDIN C; SPIRONOLACTONE;

ADULT; AGED; ARTICLE; CARDIAC RESYNCHRONIZATION THERAPY; CARDIOMYOPATHY; CLINICAL ARTICLE; CORRELATION ANALYSIS; FEMALE; FOLLOW UP; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HUMAN; MALE; QUALITY OF LIFE;

AGED; CARDIAC PACING, ARTIFICIAL; FEMALE; HEART FAILURE; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 1; MALE; MIDDLE AGED; PILOT PROJECTS; QUALITY OF LIFE; STROKE VOLUME;

EID: 34948821088     PISSN: 15582027     EISSN: None     Source Type: Journal    
DOI: 10.2459/JCM.0b013e328014a883     Document Type: Article

References (29)

1. Bristow MB. Adrenergic receptor blockade in chronic heart failure. Circulation 2000; 101:558-569.
2. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al., for the Randomized Aldactone Evaluation Study Investigators. The effects of spironolactone on mortality in patients with severe heart failure. N Engl J Med 1999; 341:709-717.
3. Cowburn PJ, Cleland JGF, Coats AJS, Komajda M. Risk stratification in chronic heart failure. Eur Heart J 1998; 19:696-710.
4. Xiao HB, Roy C, Gibson DG. Nature of ventricular activation in patients with dilated cardiomyopathy: evidence for bilateral bundle branch block. Br Heart J 1994; 72:167-174.
5. Baldasseroni S, Opasich C, Gorini M, Lucci D, Marchionni N, Marini M, et al., for the Italian Network on Congestive Heart Failure Investigators. Left bundle-branch block is associated with increased 1-year sudden and total mortality rate in 5517 outpatients with congestive heart failure: a report from the Italian network on congestive heart failure. Am Heart J 2002; 143:398-405.
6. Abraham WT, Fisher WG, Smith AL, Delurgio DB, Leon AR, Loh E, et al., for the MIRACLE Study Group. Cardiac resynchronization in chronic heart failure. N Engl J Med 2002; 346:1845-1853.
7. Cazeau S, Leclercq C, Lavergne T, Walker S, Varma C, Linde C, et al., for the Multisite Stimulation in Cardiomyopathies (MUSTIC) Study Investigators. Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay. N Engl J Med 2001; 344:873-880.
8. Ferrara R, Mastrorilli F, Pasanisi G, Censi S, D'Aiello N, Fucili A, et al. Neurohormonal modulation in chronic heart failure. Eur Heart J 2002; 4 (Suppl D):D3-D11.
9. Kjaer A, Hesse B. Heart failure and neuroendocrine activation: diagnosis, prognostic and therapeutic perspectives. Clin Physiol 2001; 21:661-672.
10. Omland T, Aakvaag A, Bonarjee VVS, Caidahl K, Lie RT, Nilsen DWT, et al. Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and long-term survival after myocardial infarction: comparison with plasma atrial natriuretic peptide and N-terminal proatrial natriuretic peptide. Circulation 1996; 93:1963-1969.
11. Le Roith D, Roberts CT Jr. Insulin-like growth factors. Ann NY Acad Sci 1993; 692:1-9.
12. Anker SD, Chua TP, Ponikowski P, Harrington D, Swan JW, Kox WJ, et al. Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia. Circulation 1997; 96:526-534.
13. Saxon LA, De Marco T, Schafer J, Chatterjee K, Kumar UN, Foster E. Effects of long-term biventricular stimulation for resynchronization on echocardiographic measures of remodelling. Circulation 2002; 105:1304-1310.
14. Braun MU, Rauwolf T, Zerm T, Schulze M, Schnabel A, Strasser RH. Long-term biventricular resynchronization therapy in advanced heart failure: effect on neurohormones. Heart 2005; 91:601-605.
15. Boriani G, Regoli F, Saporito D, Martignani C, Toselli T, Biffi M, et al. Neurohormones and inflammatory mediators in patients with heart failure undergoing cardiac resynchronization therapy: time courses and prediction of response. Peptides 2006; 27:1776-1786.
16. Michelucci A, Padeletti L, Giaccardi M, Abbate R. Natriuretic peptides and cardiac resynchronization therapy. G Ital Cardiol (Rome) 2006; 7:296-298.
17. Yu CM, Wing-Hong Fung J, Zhang Q, Sanderson JE. Improvement of serum NT-ProBNP predicts improvement in cardiac function and favourable prognosis after cardiac resynchronization therapy for heart failure. J Card Fail 2005; 11 (Suppl):S42-S46.
18. Cappola TP, Harsch MR, Jessup M, Abraham WT, Young JB, Petersen-Stejskal S, et al. Predictors of remodelling in the CRT era: influence of mitral regurgitation, BNP, and gender. J Card Fail 2006; 12:182-188.
19. Kubanek M, Malek I, Bytesnik J, Fridl P, Riedlbauchova L, Karasova L, et al. Decrease in plasma B-type natriuretic peptide early after initiation of cardiac resynchronization therapy predicts clinical improvement at 12 months. Eur J Heart Fail 2006; Mar 6 [Epub ahead of print].
20. Donath MY, Sütsch G, Yan XW, Piva B, Brunner HP, Glatz Y, et al. Acute cardiovascular effects of insulin-like growth factor I in patients with chronic heart failure. J Clin Endocrinol Metab 1998; 83:3177-3183.
21. Delafontaine P, Brink M. The growth hormone and insulin-like growth factor 1 axis in heart failure. Ann Endocrinol 2000; 61:22-26.
22. Al-Obaidi MK, Hon JKF, Stubbs PJ, Barnes J, Amersey RA, Dahdal M, et al. Plasma insulin-like growth factor-1 elevated in mild-to-moderate but not severe heart failure. Am Heart J 2001; 142:E10.
23. Kanda T, Takahashi T. Interleukin-6 and cardiovascular diseases. Jpn Heart J 2004; 45:183-193.
24. Diwan A, Tran T, Misra A, Mann DL. Inflammatory mediators and the failing heart: a translational approach. Curr Mol Med 2003; 3:161-182.
25. Russell-Jones DL, Bates AT, Umpleby AM, Hennessy TR, Bowes SB, Hopkins KD, et al. A comparison of the effects of IGF-1 and insulin on glucose metabolism, fat metabolism and the cardiovascular system in normal human volunteers. Eur J Clin Invest 1995; 25:403-411.
26. Donath MY, Jenni R, Brunner HP, Anrig M, Kohli S, Glatz Y, et al. Cardiovascular and metabolic effects on insulin-like growth factor I at rest and during exercise in humans. J Clin Endocrinol Metab 1996; 81:4089-4094.
27. Pittman JG, Cohen P. The pathogenesis of cardiac cachexia. N Engl J Med 1964; 271:403-409.
28. Anker SD, Ponikowski P, Varney S, Chua TP, Clark AL, Webb-Peploe KM, et al. Wasting as independent risk factor for mortality in chronic heart failure. Lancet 1997; 349:1050-1053.
29. Niebauer J, Pflaum CD, Clark AL, Strasburger CJ, Hooper J, Poole-Wilson PA, et al. Deficient insulin-like growth factor I in chronic heart failure predicts altered body composition, anabolic deficiency, cytokine and neurohormonal activation. J Am Coll Cardiol 1998; 32:393-397.